Shares of AIM ImmunoTech Inc. (AIM) shot up more than 66% in pre-market today, after the immuno-pharma company announced that the National Institute of Infectious Diseases or NIID in Japan will begin testing AIM's drug Ampligen as a potential treatment for COVID-19, the new coronavirus infectious disease caused by SARS-CoV-2.
from RTT - Before the Bell https://ift.tt/2xoKFDB
via IFTTT
No comments:
Post a Comment